Gene test may predict dangerous side effects in breast cancer treatment

This study explores whether certain gene variants (UGT1A1) increase the risk of severe side effects from powerful breast cancer drugs called antibody-drug conjugates. Researchers will enroll 70 adults with advanced breast cancer who are starting treatment with sacituzumab-govitecan, trastuzumab-deruxtecan, or datopotamab-deruxtecan. By analyzing participants' genes and tracking their side effects, the study aims to develop a way to predict who is most at risk, potentially leading to safer, more personalized treatment.